Cycle frequency: Every three weeks Total number of cycles: 3 or 4



Similar documents
Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Cycle frequency: Every four weeks Total number of cycles: 6-8

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

Network Chemotherapy Regimens

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue)

Thames Valley Chemotherapy Regimens

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)

Regimen: Gemcitabine & Carboplatin for NSCLC

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Chapter 7: Lung Cancer

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]

PREMEDICATIONS: Agent(s) Dose Route Schedule

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer

Hydration Protocol for Cisplatin Chemotherapy

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS Gemcitabine-1250/Carboplatin-5AUC CTIS

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

CHEMOTHERAPY PROTOCOLS V10.1

London Cancer. Mesothelioma Lung Protocols

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda ))

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.

Breast Cancer. Breast Cancer Page 1

CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago

SMALL CELL LUNG CANCER

This regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs

Prior Authorization Guideline

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

Regimen : Cetuximab ICD10 Codes pre-fixed with C18, C19, C20

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012

Activity of pemetrexed in thoracic malignancies

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

NCCP Chemotherapy Protocol. Afatinib Monotherapy

Cytotoxic and Biotherapies Credentialing Programme Module 2

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

Chemotherapy Order Assessment and Review

What s New With HER2?

Network Chemotherapy Protocols

Adverse Effects of Chemotherapy

Calcium Folinate Ebewe Data Sheet

Avastin in breast cancer: Summary of clinical data

Cancer Drug Toxicities and Anaesthesia

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG study results presented at ASCO 2004

Chemotherapy for non-small cell lung cancer

Chemotherapy for lung cancer

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients

Update on Small Cell Lung Cancer

New Treatment Options for Breast Cancer

IV Thiotepa/Busulfan/Fludarabine/ATG for Allograft

Avastin in breast cancer: Summary of clinical data

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT

Testicular Cancer. Page 1 of 17 TABLE OF CONTENTS

Regimen : Bevacizumab for metastatic colorectal cancer ICD10 codes pre-fixed with: C18, C19, C20

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Shared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

Case Report in Oncology Pharmacy. Therapy and supportive care of a high-grade non-hodgkin s lymphoma

BCCA Protocol Summary for Combined Chemotherapy CISplatin and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Chemotherapy for head and neck cancers

Stage I, II Non Small Cell Lung Cancer

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

London Cancer Systemic Treatment for Breast Cancer

TCH: Docetaxel, Carboplatin and Trastuzumab

NCCN Non-Small Cell Lung Cancer V Update Meeting 07/09/10

Transcription:

BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs Days 1 & 2 Cycle frequency: Every three weeks Total number of cycles: 3 or 4 Anti-emetic group High Delay if neutrophils < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L No Bleomycin with 4 th cycle Pre & post hydration, mannitol, potassium & magnesium Do not cap BSA vomiting, mucositis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, pneumonitis, pulmonary fibrosis, constipation, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance, lung function (inc. DLCO), CXR, Audiometry Prior to each cycle (and Day 8 & 15 Bleomycin): CXR (Day 1 only) Limited CT scan Day 20 after 1 st cycle. See at start of each cycle Reference: Williams et al, 1987. N. Engl. J. Med., 316; pages 1435-1440 3 rd Edition 62

BEP 5-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Etoposide 100mg/m 2 1L N. Saline/1hr Days 1-5 Cisplatin 20mg/m 2 1L N. Saline/4hrs Days 1-5 Bleomycin 30,000iu 200mls N. Saline/30min Days 2, 8 & 15 Cycle frequency: Every three weeks Total number of cycles: 3 or 4 Anti-emetic group - High Delay if neutrophils < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L No Bleomycin with 4 th cycle Pre and post-hydration and mannitol Do not cap BSA vomiting, mucositis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, pneumonitis, pulmonary fibrosis, constipation, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance, lung function (inc. DLCO), CXR, Audiometry Prior to each cycle (and Day 8 & 15 Bleomycin): CXR (Day 1 only) Limited CT scan Day 20 after 1 st cycle. See at start of each cycle Reference: Nichols et al, 1998. J. Clin. Oncol., 16; pages 1287-1293 3 rd Edition 63

Carboplatin Seminoma stage 1 adjuvant Carboplatin AUC 7 500mls 5% dex/1hr Day 1 Cycle frequency: Once Total number of cycles: 1 Anti-emetic group - Moderately high Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 7 plus 10% vomiting Symptomatic treatment of side effects: Mouth care U & E s, LFTs, creatinine, urate, creatinine clearance, HCG and AFP Review in Medical Oncology Clinic 2 weeks after treatment Reference: Oliver et al, 2005, Lancet, 366; pages 267-268 3 rd Edition 64

VIP (Vinblastine/Ifosfamide/Cisplatin) Germ cell tumours - Recurrent Vinblastine 0.11mg/kg/day 250mls N. Saline/30min Days 1 & 2 Ifosfamide 1200mg/m 2 1L N. Saline/4hrs Days 1-5 Cisplatin 20mg/m 2 1L N. Saline/2hrs Days 1-5 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Delay if neutrophils < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L Pre & post hydration, mannitol, potassium & magnesium Etoposide (75 mg/ m 2 days 1-5) instead of Vinblastine in some cases Mesna dose guidelines Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance, lung function (inc. DLCO), Audiometry, CXR CXR See at start of each cycle Reference: Loehrer et al, 1998. Ann. Intern. Med., 109; pages 540-546 3 rd Edition 65

TIP (Paclitaxel/Ifosfamide/Cisplatin) Germ cell tumours Recurrent Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Ifosfamide 1000mg/m 2 1L N. Saline/4hrs Days 1-5 Cisplatin 20mg/m 2 1L N. Saline/4hrs Days 1-5 Cycle frequency: Every three weeks Total number of cycles: 4 Dose medication: Discuss with Consultant Anti-emetic group High Delay if neutrophils < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L Pre & post hydration, mannitol, potassium & magnesium Pre-medication (chlorpheniramine, ranitidine, dexamethasone) prior to Paclitaxel Mesna 1g/m 2 per 24 hours MgSO 4 and KCI in pre-hydration, with 100mls mannitol (20%) iv bolus if urinary output low Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility Pre-treatment, urate, creatinine clearance, lung function (inc. DLCO), Audiometry, CXR CXR Post treatment: See at start of each year Reference: Mead et al, 2005. Br. J. Cancer, 25; pages 178-184 3 rd Edition 66

Modified Wetlauffer (M-BOP) Recurrent Germ cell tumours Bleomycin 15,000iu 250mls N. Saline/30 min Days 1, 8 & 15 Vincristine 2mg iv Days 1, 8 & 15 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1, 2, 8, 15 & 16 Methotrexate 25mg iv Day 8 Cycle frequency: 35 days Total number of cycles: 4 Anti-emetic group - High Delay if neutrophils < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L No Bleomycin if low DLCO Pre and post hydration, mannitol, potassium & magnesium Prophylactic PPI and co-trimoxazole Do not cap BSA vomiting, mucositis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, pneumonitis, pulmonary fibrosis, constipation, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance, lung function (inc. DLCO), CXR, Audiometry Prior to each cycle CXR (Day 1 only) Reference: Shamash et al, 1999. Ann. Oncol., 10; pages 685-692 3 rd Edition 67

BOPq10 (Bleomycin/Vincristine/Cisplatin) Germ cell tumours - adjuvant Bleomycin 30,000iu 200mls N. Saline/30mins Day 1 Vincristine 2mg iv Day 1 Cisplatin 50mg/m 2 1L N. Saline/4hrs Days 1 & 2 Cycle frequency: 10 days Total number of cycles: 2 Anti-emetic group High Delay if neutrophils < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L Pre & post hydration, mannitol, potassium & magnesium Do not cap BSA vomiting, mucositis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, pneumonitis, pulmonary fibrosis,constipation, diarrhoea, infertility, urate, creatinine clearance,, lung function (inc. DLCO), CXR, Audiometry CXR (Day 1 only) Reference: Kaye et al, 1998. J. Clin. Oncol., 16; pages 692-701 3 rd Edition 68

EP (Epirubicin/Cisplatin) Germ Cell Recurrent, Refractory Drug Dose in/infusion/oral q Epirubicin 45mg/m 2 iv Days 1 & 2 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function Hickman line required Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance CXR Reference: Bedano et al, 2005, ASCO Abstract 4526. 3 rd Edition 69

Interferon alpha Renal Cell Carcinoma Metastatic, Recurrent Interferon α2a 5mU s/c X3/wk for 2wks Then 10mU s/c X3/weekly Cycle frequency: For three months Total number of cycles: 2 Anti-emetic group - Low Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Self-administration Plan Bevacizumab if required Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, flulike symptoms, anorexia, lethargy, joint aches Symptomatic treatment of side effects: Mouth care, Paracetamol, administer treatment in evening U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine See monthly and re-assess after 3 months Reference: MRC, 1999. Lancet, 353; pages 14-17 3 rd Edition 70

Cisplatin/Gemcitabine Bladder Cancer - Advanced Cisplatin 70mg/m 2 1L N. Saline/2hrs Day 1 Gemcitabine 1000mg/m 2 200mls N. Saline/30mins Days 1, 8 &15 Cycle frequency: Every four weeks Total number of cycles: 4 Anti-emetic group High Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Pre & post hydration, mannitol, potassium & magnesium If unable to tolerate, omit day 15 and give treatment every 3 weeks vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance CXR CXR After every two cycles Reference: van der Maase et al, 2000. J. Clin. Oncol., 18; pages 3068-3077 3 rd Edition 71

CMV (Cisplatin/Methotrexate/Vinblastine) Bladder Advanced, Recurrent Methotrexate 30mg/m 2 iv Days 1 & 8 Vinblastine 4mg/m 2 iv Days 1 & 8 Cisplatin 100mg/m 2 1L N. Saline/4hrs Day 2 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group - High Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Pre & post hydration, mannitol, potassium & magnesium Cisplatin to start 12 hours after methotrexate vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every two cycles Reference: Harker et al, 1985. J. Clin. Oncol., 11; pages 1463-1470 3 rd Edition 72

MOPq10 (Methotrexate/Vincristine/Cisplatin) Bladder Advanced, Recurrent Methotrexate 60mg/m 2 iv Day 1 Vincristine 2mg iv Day 1 Cisplatin 60mg/m 2 1L N. Saline/2hrs Day 1 Cycle frequency: Every 10 days Total number of cycles: 4 Anti-emetic group High Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Cisplatin to start 12 hours after methotrexate Pre & post hydration, mannitol, potassium & magnesium Calcium Folinate rescue (15mg qds x 4 doses) for all patients with hydronephrosis vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After each cycle. Reference: Boshoff et al, 1995. Eur. J. Cancer, 31A; pages 1633-1636 3 rd Edition 73

MP (Mitozantrone/Prednisolone) Prostate Cancer Recurrent, Metastatic, Hormone refractory Mitozantrone 12mg/m 2 100mls N. Saline/10mins Day 1 Prednisolone 10mg od oral Daily Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group - Moderate Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, mucositis, steroid side effects, discoloured urine, liver function tests, diarrhoea Symptomatic treatment of side effects: Mouth care U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine After every two cycles Reference: Tannock et al, 1996. J. Clin. Oncol., 14; pages 1756-1764 3 rd Edition 74

Docetaxel/Prednisolone Prostate Cancer hormone refractory Docetaxel 75mg/m 2 250mls N. Saline/1hr Day 1 Prednisolone 5mg bd oral Days 1-21 Cycle frequency: Every three weeks Total number of cycles: up to 10 Anti-emetic group Low Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Pre-medication dexamethasone 8 mg (oral or iv) at 12 hours, 3 hours and I hour before docetaxel infusion vomiting, mucositis, alopecia, peripheral neuropathy, fluid retention, hypersensitivity reaction, skin rash, and side-effects of steroids. Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate, PSA U & E s, LFTs, creatinine, PSA Re-assess after 2 cycles Reference: Tannock et al, 2004. N. Engl. J. Med., 351; pages 1502-1512 3 rd Edition 75